Unicycive Therapeutics, Inc.
NASDAQ:UNCYBiotechnology
-$0.24 today
- Market cap
- $104.19M
- Beta
- 1.73
- P/E (TTM)
- -40.8
- EPS (TTM)
- -$0.17
Volume 1.39M
Average 0.65M
UNCY Operating Cash Flow
Cash generated by the company's core business operations during the period.
Unicycive Therapeutics, Inc.NASDAQ: UNCY
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow declines year over year
Q1 FY2026 operating cash flow of $6.24M (cash outflow) fell 29.9% year over year, behind the -7.6% change in trailing-twelve-month operating cash flow. Sequentially, it fell 22.3% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -29.9% toward the trailing-twelve-month pace of -7.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (31.32M) USD
- Year-over-year change
- -9.6%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (31.32M) | -9.6% |
| FY2024 | 2024-12-31 | (28.58M) | -56.3% |
| FY2023 | 2023-12-31 | (18.28M) | -16.8% |
| FY2022 | 2022-12-31 | (15.65M) | -171.4% |
| FY2021 | 2021-12-31 | (5.77M) | — |
Operating Cash Flow vs competitors
How UNCY compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.6% is the 6th highest of 10, against a peer median of -5.1%.
- Over three fiscal years its annual growth of +26.0% compares with a peer median of +4.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $81.33M USD | -1.5% | +9.6% | — | |
| LTM Mar 2026 | $74.99M USD | +40.5% | +4.9% | — | |
ACRVAcrivon Therapeutics, Inc. Common Stock | LTM Mar 2026 | $64.67M USD | -5.1% | +28.3% | — |
| LTM Mar 2026 | $56.25M USD | -50.5% | +4.1% | — | |
CBUSCibus, Inc. | LTM Mar 2026 | $50.25M USD | -10.9% | +37.7% | 1172.4% |
| LTM Mar 2026 | $42.79M USD | -24.7% | -23.9% | — | |
| LTM Mar 2026 | $28.66M USD | -7.6% | +26.0% | — | |
| LTM Mar 2026 | $26.25M USD | -46.1% | — | 667.2% | |
| LTM Mar 2026 | $15.26M USD | +146.0% | — | 6.0% | |
HYFTMindWalk Holdings Corp. | LTM Jan 2026 | CA$11.15M CAD | +40.9% | -13.5% | 60.7% |
| Peer median (excluding UNCY) | — | -5.1% | +4.9% | 364.0% | |
Competitors are the stored peer set for UNCY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (10.02M) | (18.06M) | (30.54M) | (36.73M) | (26.56M) |
| Depreciation & Amortization | 13K | 161K | 284K | 428K | 572K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 966K | 1.05M | 1.77M | 2.35M | 2.64M |
| Change in Working Capital | (105K) | 1.18M | (93K) | (427K) | (5.95M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.24M | 1.27M | 1.28M | 790K | (2.51M) |
| Other Working Capital | (1.35M) | (89K) | (1.37M) | (1.22M) | (3.45M) |
| Other Non-Cash Items | 3.38M | 21K | 10.3M | 5.8M | (2.02M) |
| Operating Cash Flow | (5.77M) | (15.65M) | (18.28M) | (28.58M) | (31.32M) |
| Capital Expenditures | (29K) | (2K) | (12K) | (72K) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | (12.07M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (29K) | (2K) | (12K) | (72K) | (12.1M) |
| Debt Repayment | (15K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 22.27M | 11K | 0 | 683K | 48.08M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | (1.1M) | 0 |
| Other Financing Activities | 119K | (482K) | (2.65M) | (4.5M) | (1.61M) |
| Financing Cash Flow | 22.38M | (471K) | 27.54M | 45.09M | 46.47M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 16.58M | (16.12M) | 9.25M | 16.44M | 3.06M |
| Free Cash Flow | (5.8M) | (15.65M) | (18.3M) | (28.65M) | (31.34M) |
Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Intrinsic Alpha fair value
Locked
Current Price
$3.57
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.